Oculis (NASDAQ:OCS) Shares Gap Up – Should You Buy?

Oculis Holding AG (NASDAQ:OCS)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $16.93, but opened at $17.64. Oculis shares last traded at $17.45, with a volume of 51,109 shares trading hands.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Oculis in a research note on Monday, November 11th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $29.20.

Oculis Trading Up 3.7 %

The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The business’s fifty day moving average is $16.32 and its 200-day moving average is $13.74. The firm has a market cap of $711.25 million, a P/E ratio of -9.10 and a beta of -0.33.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.